COTA White Paper Spotlights Perspectives on RWE

February 19, 2020

A new white paper from COTA offers unique perspectives on real-world evidence (RWE), including input from Pfizer and Bristol-Myers Squibb executives.

COTA says that while RWE shows some promise, there are a number barriers preventing widespread adoption.

“In 2020, we expect many of these challenges to be addressed by stakeholders across the industry as they collaborate to make drug development more efficient, ultimately getting the best drugs to patients faster and less expensively,” COTA says.

To learn more about this white paper, click here.

Share This Story!